South Texas Alzheimer’s Disease Center Biomarker Core

南德克萨斯阿尔茨海默病中心生物标志物核心

• 批准号: 10270726
• 负责人: Xianlin Han
• 金额: $ 10.25万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10270726
• 关键词: Alzheimer' s Disease; Amyloid; Basic Science; Biochemical; Biological Assay; Biological Markers; Biology; Blood; Brain; Capsicum; Catalogs; Cerebrovascular Trauma; Clinical; Clinical Research; Clinical Trials; Cognition; Collaborations; Collection; Communication; Communities; DNA; Data; Dementia; Development; Diagnosis; Differential Diagnosis; Disease; Doctor of Philosophy; Early Diagnosis; Endothelium; Enrollment; Exclusion Criteria; Feces; Functional disorder; Funding; Genomics; Goals; Grant; Heterogeneity; Hispanics; Image; Individual; International; Link; Magnetic Resonance Imaging; Measures; Metabolic; Methods; Molecular; Motor; Nerve Degeneration; Neurosciences; Non-Insulin-Dependent Diabetes Mellitus; Nuclear Pore Complex; Onset of illness; Participant; Patient Care; Patient Recruitments; Patients; Pattern; Persons; Plasma; Population; Positron-Emission Tomography; Prevalence; Procedures; Process; Protocols documentation; RNA; Research Personnel; Resources; Saliva; Sampling; Sensory; Serum; Services; South Texas; Supervision; System; Time; Translational Research; Visit; Work; biobank; biomarker development; clinical Diagnosis; clinical center; cohort; data management; disease heterogeneity; disorder risk; disorder subtype; flexibility; fluorodeoxyglucose positron emission tomography; follow-up; genomic data; improved; inflammatory marker; insight; lipidomics; metabolomics; monocyte; multiple omics; neurodegenerative dementia; neuropathology; normal aging; novel; novel marker; peripheral blood; personalized medicine; pre-clinical; prodromal Alzheimer' s disease; prognostic; repository; research study; risk prediction; symposium

Biomarkers permit a deeper understanding of biology, improve risk prediction, diagnosis and prognostication at pre-clinical and clinical stages of Alzheimer Disease and Related Disorders (ADRD). The overall goals of the Biomarker core (BC) are two-fold: (1) To provide ante-mortem biobanking services for STAC, that is to collect and store biospecimens for all persons enrolled in the Clinical Core (patients, care partners and controls), an estimated 265/year at their initial and annual follow-up visits, and similarly collect and store biospecimens for persons not enrolled in the CC but referred by another STAC core (e.g. population core study enrollees, clinical trial patients, brain bank donors) and working with the Data, Statistical Management and Administrative Cores catalog, track and share these samples. (2) To identify biomarkers for detecting preclinical ADRD, for risk prediction of progression to MCI and ADRD dementia, and for differential diagnosis and identifying subtypes of ADRD MCI and dementia. The BC is led by Xianlin Han, PhD, a leader in AD metabolomics/lipomics and Mini Jacob, MD, PhD, studying sensory-motor biomarkers in ADRD. We have added Co-I Sara Espinoza, MD, a senior geriatrician who is Director of the GRECC and Pepper Center Clinical Core. To achieve these goals: Firstly, we will collect, process, store, share and track biospecimens (serum, plasma, peripheral blood monocytes, DNA, RNA, CSF and saliva or stool when indicated), as well as non-invasive sensorimotor measures from individuals and link to their clinical, imaging, genomic and neuropathologic data. We will use the latest biochemical and molecular methods and apply best practice procedures. Secondly, we will validate or identify biomarkers among the Hispanic population by collaborating with the CC, PNC, GMC, IC and NPC to correlate the markers with clinical diagnoses, course of disease, imaging and neuropathology. We will make these data publicly available by submitting samples and curated data to repositories such as NACC, NCRAD and NIAGADS. Thirdly, we will identify novel CSF and plasma metabolic biomarkers in individuals with Suspected Non-Alzheimer Pathophysiology (SNAP) with or without type 2 diabetes mellitus (T2DM). In collaboration with the CC, PNC and IC we will identify individuals with SNAP with and without T2DM (300-400 in total, half T2DM at rate of ~80/year), identify plasma metabolic biomarkers distinguishing between classical biomarker-defined AD (A+/T+/N+) and SNAP in persons with and without T2DM. We expect to find a unique biomarker and metabolic signature in SNAP compared to AD and in SNAP with T2DM that will help us better understand the biology of SNAP and may help with diagnosis and treatment. In summary, BC will collect and share biospecimens, and generate and share extensive biomarker data in Hispanics to establish a unique resource for understanding the heterogeneity of ADRD in South Texas and for development of AD personalized treatments.

生物标志物可以更深入地了解生物学，改善风险预测、诊断和预测 阿尔茨海默病及相关疾病 (ADRD) 的临床前和临床阶段。的总体目标 生物标志物核心（BC）有两个方面：（1）为STAC提供生前生物样本库服务，即 为所有参与临床核心的人员（患者、护理伙伴和 控制），估计每年 265 次，在初次和每年的后续访问中，并类似地收集和存储 未加入 CC 但由另一个 STAC 核心转介的人员的生物样本（例如人口核心研究 参与者、临床试验患者、脑库捐赠者）并与数据、统计管理和 管理核心对这些样本进行编录、跟踪和共享。 (2) 鉴定检测用生物标志物 临床前 ADRD，用于进展为 MCI 和 ADRD 痴呆的风险预测以及鉴别诊断 识别 ADRD MCI 和痴呆症的亚型。 BC 由 AD 领域的领军人物韩贤林博士领导 代谢组学/脂质组学和 Mini Jacob 博士，研究 ADRD 中的感觉运动生物标志物。我们有 补充说，Co-I Sara Espinoza 医学博士是一位高级老年病学家，也是 GRECC 和 Pepper 中心临床主任 核。为了实现这些目标：首先，我们将收集、处理、存储、共享和跟踪生物样本 （血清、血浆、外周血单核细胞、DNA、RNA、脑脊液和唾液或粪便（如有需要），以及 来自个体的非侵入性感觉运动测量，并与其临床、影像、基因组和 神经病理学数据。我们将使用最新的生化和分子方法并应用最佳实践 程序。其次，我们将通过以下方式验证或识别西班牙裔人群中的生物标志物： 与 CC、PNC、GMC、IC 和 NPC 合作，将标记物与临床诊断、病程相关联 疾病、影像学和神经病理学。我们将通过提交样本和公开这些数据 将数据整理到 NACC、NCRAD 和 NIAGADS 等存储库中。第三，我们将确定新型 CSF 和 疑似非阿尔茨海默病病理生理学 (SNAP) 个体的血浆代谢生物标志物 患有或不患有 2 型糖尿病 (T2DM)。与 CC、PNC 和 IC 合作，我们将确定 患有 SNAP 并伴有或不伴有 T2DM 的个体（总共 300-400 人，其中一半 T2DM 的比率约为 80 人/年），识别血浆 区分人体经典生物标志物定义的 AD (A+/T+/N+) 和 SNAP 的代谢生物标志物 有和没有 T2DM。我们期望在 SNAP 中找到独特的生物标志物和代谢特征。 AD 和 SNAP 与 T2DM 这将帮助我们更好地了解 SNAP 的生物学，并可能有助于 诊断和治疗。综上所述，BC将收集和共享生物样本，并生成和共享 西班牙裔的广泛生物标志物数据，为了解西班牙裔的异质性建立了独特的资源 ADRD 位于德克萨斯州南部，致力于开发 AD 个性化治疗。